Isomorphic Labs raises $5 billion for AI drug discovery
Alphabet-backed Isomorphic Labs has secured a record-scale Series C to expand AI-native drug design and move more candidates toward patients.
Isomorphic Labs has raised $5 billion in a Series C round to scale its AI drug-design platform and therapeutic pipeline. The financing was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and continued significant backing from Alphabet and the company’s existing investors.
A second mega-round in six months
The company says the funding will accelerate development of its proprietary IsoDDE engine and support the design of new medicines. Existing backers include Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The round follows another large financing earlier in the year, making the pace of capital formation almost as notable as the headline amount.
Isomorphic Labs was founded around the idea that AI can improve drug discovery by modeling biological interactions and proposing therapeutic candidates with greater speed and precision. Its connection to Alphabet gives it access to research lineage associated with DeepMind’s work on protein structure and biological modeling, while its commercial focus is on turning those capabilities into drug programs.
Capital is moving closer to the laboratory
The round is significant because it finances an operating model that sits between a software company and a biotechnology firm. Training and deploying advanced biological models requires substantial compute and data, but successful products also need wet-lab validation, toxicology, clinical development and regulatory approval. A large balance sheet can sustain those expensive transitions, but it cannot remove the scientific uncertainty between a promising model output and an approved medicine.
Alphabet’s continued participation also signals that the parent company sees drug discovery as a strategic AI application rather than a side project. The investor mix broadens the company’s financial base while keeping a major technology platform closely involved.
Why it matters
This is one of the clearest signs that AI capital is moving from general-purpose model competition into domain-specific scientific infrastructure. The $5 billion commitment will be judged less by software benchmarks than by whether Isomorphic can produce validated candidates, partnerships and eventually medicines; that conversion remains the central unanswered question.